Anti-C5a antibody STSA-1002 for patients with acute respiratory distress syndrome due to viral pneumonia: a phase 1b/2, multicenter, randomized, double-blind, placebo-controlled trial.
Summary
This multicenter phase 1b/2 randomized double‑blind trial enrolled 49 patients with viral‑pneumonia ARDS. STSA‑1002 was well tolerated and the higher dose (1350 mg) showed a non‑significant trend toward faster clinical improvement (TTCI) versus placebo; safety profile was favorable and warrants phase 3 evaluation.
Key Findings
- STSA‑1002 administration was associated with a favorable safety profile in patients with viral‑pneumonia ARDS.
- Higher dose (1350 mg) showed a non‑significant trend to shorter time to clinical improvement (TTCI) compared with placebo (sHR 1.55; 95% CI 0.68–3.55).
- Study size (n=49) limits statistical power; findings are hypothesis‑generating for a phase 3 trial.
Clinical Implications
If confirmed in phase 3, C5a blockade could become a targeted immunomodulatory therapy for viral‑pneumonia ARDS; currently, results are insufficient to change practice but justify further trials.
Why It Matters
First randomized clinical evidence that complement C5a blockade with STSA‑1002 is safe in viral‑pneumonia ARDS and shows efficacy signals, justifying larger phase 3 trials.
Limitations
- Small sample size (49 randomized; 47 treated) limits power to detect efficacy.
- Abstract truncation limits availability of full secondary endpoint and safety details in provided data.
Future Directions
Proceed to a adequately powered phase 3 randomized trial to confirm efficacy, stratify by viral etiology and severity, and collect mechanistic biomarkers (complement activation, inflammatory markers).
Study Information
- Study Type
- RCT
- Research Domain
- Treatment
- Evidence Level
- II - Early‑phase randomized controlled trial (phase 1b/2) providing preliminary efficacy and safety data.
- Study Design
- OTHER